
Antisense Therapeutics to Present at Webinar Hosted by Parent Project Muscular Dystrophy in the US

Antisense Therapeutics (ASX:ANP | US OTC:ATHJY) will present on the final results from its Phase II clinical trial of the Company's immunomodulatory therapy, ATL1102 in boys with Duchenne Muscular Dystrophy (DMD) at a webinar hosted by Parent Project Muscular Dystrophy (PPMD) at 1 p.m. ET on June 17 in the US.

PPMD is the largest most comprehensive non-profit organization in the United States focused on finding a cure for DMD - their mission is to end DMD. PPMD accelerates research, raises voices to impact policy, demands optimal care for every single family, and strives to ensure access to approved therapies. PPMD invest deeply in treatments for people affected by Duchenne and in research that will benefit future generations. PPMD advocate in Washington, DC, and have secured hundreds of millions of dollars in funding.

The Phase II clinical trial of ATL1102 was an open label six-month dosing trial of ATL1102 in nine non-ambulant patients with DMD. The trial was conducted at the neuromuscular centre of the Royal Children's Hospital in Melbourne, Australia. The primary endpoints of the trial related to the safety and tolerability of ATL1102. ATL1102 met the primary endpoint of the study with confirmation of the drug's safety and tolerability. ATL1102 also demonstrated strong effects on secondary endpoints including activity on the targeted CD49d immune cells consistent with the drug's proposed mechanism of action and outcomes on disease progression parameters that exceeded the Company's expectations with improvement or stabilisation across different measures of muscle function and strength. The positive effects on disease progression were further supported by MRI data that suggested a stabilisation in the percentage of fat fraction in the muscles and preservation of functional muscle mass.

Speakers

- Pat Furlong, PPMD President
- Mark Diamond, Antisense Therapeutics Chief Executive Officer
- Nuket Desem, Antisense Therapeutics Director of Clinical and Regulatory affairs
- Gil Price, M.D., Antisense Therapeutics Medical Director

The presentation will be recorded and accessible via the PPMD website

<https://www.parentprojectmd.org/>

For more information please contact:

Antisense Therapeutics

Mark Diamond
Managing Director
+61 (0)3 9827 8999
www.antisense.com.au

Investment Enquiries

Gennadi Koutchin
XEC Partners
gkoutchin@xecpartners.com.au
+61 423 500 233

US Enquiries

Erin Cox
erin.cox@antisense.com.au
+1 206 579 3457

About Antisense Therapeutics is an Australian publicly-listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development. The Company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne Muscular Dystrophy (DMD) patients and recently reported highly promising Phase II trial results. ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The Company has a second drug, ATL1103 designed to block GHr production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.